Clinical Trials Logo

C3 Glomerulonephritis clinical trials

View clinical trials related to C3 Glomerulonephritis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03459443 Terminated - C3 Glomerulopathy Clinical Trials

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.

NCT ID: NCT01791686 Terminated - Clinical trials for Dense Deposit Disease

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

Start date: January 2013
Phase: Phase 1
Study type: Interventional

This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.